Brokerages Set CONMED Corporation Price Target at $52.83

Analysts maintain 'Hold' rating on medical device company's stock

Mar. 3, 2026 at 1:55am

Got story updates? Submit your updates here. ›

CONMED Corporation (NYSE:CNMD) has received a consensus 'Hold' rating from eight research firms covering the company, with an average 12-month price target of $52.83. Analysts have cited mixed factors, with some upgrading the stock to 'Buy' while others have lowered their price targets due to near-term challenges.

Why it matters

CONMED is a major medical device manufacturer, so analyst sentiment and price targets can impact investor confidence and the company's ability to raise capital. The mixed ratings reflect the complex landscape facing the healthcare industry, with factors like regulatory changes and supply chain disruptions affecting performance.

The details

The eight research firms covering CONMED have provided a range of recommendations, with one 'Sell', six 'Hold', and one 'Buy' rating. Price targets have ranged from $52 to $68, with the average at $52.83. Factors cited include a drop in the company's share price, challenges in certain product lines, and uncertainty around the broader economic environment.

  • The analyst ratings and price targets were issued over the past year, from November 2025 to February 2026.

The players

CONMED Corporation

A global medical technology company headquartered in Utica, New York that develops, manufactures and markets surgical devices and accessories for minimally invasive procedures.

Wall Street Zen

An equity research firm that upgraded CONMED's rating from 'Hold' to 'Buy'.

JPMorgan Chase & Co.

A major investment bank that lowered its price target on CONMED shares.

Piper Sandler

An investment banking and institutional securities firm that reduced its price target on CONMED.

Zacks Research

An equity research firm that upgraded CONMED's rating from 'Strong Sell' to 'Hold'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The mixed analyst sentiment on CONMED reflects the broader challenges facing the medical device industry, with factors like regulatory changes and economic uncertainty impacting performance. However, the company's diversified product portfolio and focus on minimally invasive procedures could position it for long-term growth if it can navigate near-term headwinds.